Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance

Author:

McNeil Ewan M.,Astell Katy R.,Ritchie Ann-Marie,Shave Steven,Houston Douglas R.,Bakrania Preeti,Jones Hayley M.,Khurana Puneet,Wallace Claire,Chapman Tim,Wear Martin A.,Walkinshaw Malcolm D.,Saxty Barbara,Melton David W.

Funder

MD Anderson

Cancer Research UK

MRC

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference51 articles.

1. CancerStats, Cancer Research UK, 2015. http://www.cancerresearchuk.org/cancer-info/cancerstats/.

2. Developing melanoma therapeutics: overview and update;Korman;Wiley Interdiscip. Rev. Syst. Biol. Med.,2013

3. DNA repair endonuclease ERCC1–XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy;McNeil;Nucleic Acids Res.,2012

4. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer;Simon;Chest,2005

5. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy;Olaussen;N. Engl. J. Med.,2006

Cited by 60 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3